Reg CF in 2026: What 5 Years of EDGAR Data Tell Us About Actual Returns

Reg CF in 2026: What 5 Years of EDGAR Data Tell Us About Actual Returns

TL;DR: Of the 9,461 Reg CF offerings initiated since 2016, fewer than half — 4,303, or 45% — have reported any proceeds to the SEC at all. The median successful company that raised money had $10,000 in annual revenue and 3 employees, yet entered at a $15 million valuation. Capital raised has fallen 31% from the 2021 peak. Here's what the numbers actually say.

The Promise vs. The Data

When Congress passed the JOBS Act in 2012 and the SEC opened Reg CF (Regulation Crowdfunding) to the public in May 2016, the pitch was straightforward: democratize startup investing. Let everyday people put money into the next great American company the way venture capitalists do. Give Main Street access to the deals that once belonged exclusively to Sand Hill Road.

I've watched this play out across hundreds of deals now. The promise was real enough to generate $1.546 billion in disclosed capital formation across 4,303 funded offerings through December 31, 2025, according to the SEC Statistics page, updated March 17, 2026. The problem is what that headline number hides.

This is a data journalism piece. I'm not here to tell you Reg CF is bad. I'm here to show you what five years of EDGAR filings actually look like when you read the numbers straight. The underlying Form C data is available directly from the SEC Crowdfunding Offerings Data Sets.

The Headline Statistic Nobody Advertises

Start with the most important number: 9,461 Reg CF offerings initiated through December 31, 2025. Of those, 4,303 — just 45.5% — reported any proceeds at all via Form C-U filings. Another 1,063 offerings were withdrawn before close.

That means more than half of every company that launched a Reg CF offering either failed to raise a single dollar they were willing to report, or pulled the plug entirely. This is not a knock on the structure of the law. It's a baseline fact about the quality distribution of companies using the exemption.

The SEC's own Division of Economic and Risk Analysis (DERA) white paper, authored by Angela Huang and Vladimir Ivanov in May 2025, describes the issuer profile at time of offering with unusual candor:

"The crowdfunding exemption continues to gain momentum over time and serve small and early-stage companies seeking access to capital, often for the first time. [However] only about one out of seven issuers had recorded a net profit."

One in seven. That's 14.3% of companies that came to the crowd having demonstrated they could earn more than they spend. The other six out of seven were pre-profit at minimum — in many cases, pre-revenue.

The Valuation Problem

Here is the number that should give any angel investor pause. The SEC DERA white paper documented the median Reg CF issuer's financial profile at time of offering: approximately $80,000 in total assets, $13,000 in cash, $60,000 in debt, $10,000 in annual revenue, and 3 employees.

KingsCrowd's 2024 annual report documented the median offering valuation: $15.0 million. The average was $36.5 million.

Do the math. A company with $10,000 in annual revenue raising money at a $15 million valuation is entering at a 1,500x revenue multiple. For comparison, the median Series A SaaS company in 2024 entered at roughly 8-15x revenue — and those companies had growth curves, customer traction, and institutional due diligence behind the number.

Retail Reg CF investors are paying VC-level entry prices for companies that professional VCs almost universally passed on. A 2021 working paper from researchers at UT Austin McCombs found that crowdfunded firms face "severe adverse selection" and are "less likely to progress through the financing funnel and thus provide exit to investors" compared to angel-backed peers. That study analyzed EDGAR data directly. It's the closest thing to a systematic returns analysis we have, and its conclusion is not encouraging.

Understanding how startup valuations work is essential context before committing capital to any early-stage deal, whether through Reg CF or a traditional angel syndicate.

Five Years of Capital: The Trend Line

The year-by-year picture tells a story the booster community has been reluctant to discuss plainly.

Reg CF Annual Capital Formation Summary: 2021–2025

Year	Capital Raised	New Offerings	Median Raise (Successful)	Funding Success Rate
2021	~$487M	1,448	~$450K avg	89.3% (equity)
2022	~$494M	~1,500+	$1,256 avg check	~80%
2023	$420M	1,434	$366K avg raise	79%
2024	$343.6M	1,408	$114K median / $368K avg	69%
2025	$378.3M	~999 (est.)	$194K median / $572K avg	n/a

Sources: KingsCrowd annual reports 2021–2025; SEC DERA White Paper May 2025. Note: 2022 figures vary between KingsCrowd ($423M) and Crowdwise ($494M) due to investment-date vs. close-date attribution methodology.

2021 was the peak, driven by near-zero interest rates, stimulus cash, and a retail investing frenzy that also drove the meme stock era. By 2024, total capital raised had fallen to $343.6 million — a 31% drop from peak. The funding success rate fell from 89.3% to 69%. That means roughly 3 in 10 companies that launched a Reg CF campaign in 2024 did not reach their minimum funding goal.

2025 showed a partial recovery to $378.3 million — up 11% from 2024 — but on 29% fewer new offerings. Larger rounds from a smaller pool of companies drove the number up. That is a consolidation signal, not a recovery signal.

Q1 2026 data does not improve the picture: capital raised dropped 29% year-over-year to $72.4 million versus $101.9 million in Q1 2025, while new offerings fell 42%. The structural contraction continues.

Where the Money Concentrated

Three platforms captured 67% of all Reg CF capital in 2024: Wefunder ($99M), StartEngine ($86M), and DealMaker ($49M), according to the KingsCrowd 2024 Investment Crowdfunding Annual Report. Republic, once a top-three player at $91.3M in 2022, dropped to fourth place at $15.6M in 2024 — an 83% decline in three years.

This matters for two reasons. First, if you're comparing crowdfunding platforms, the market has sorted itself: two or three platforms now function as the effective infrastructure of the industry. Second, platform concentration creates platform risk. When Mainvest — the eighth-largest platform in 2023, having facilitated $7.8M in raises — shut down in June 2024, every company that had raised through it lost its intermediary relationship for ongoing investor communications and annual C-AR filings. The investors in those companies were left holding securities with no active platform support.

Platform failure is a real risk in Reg CF. It is not discussed nearly enough.

Only 92 raises exceeded $1 million in 2024 — just 7% of all closed rounds that year. And as of mid-2023, only 41 companies had ever hit the $5M statutory maximum in the entire history of Reg CF. The long tail of small raises ($114K median in 2024) is not the story that gets told at pitch competitions, but it is the statistical reality of the market.

NowRx: What a $27 Million Raise Looks Like Six Months Later

The case study that every Reg CF investor should read is NowRx, a pharmacy delivery startup. In June 2022, NowRx closed one of the largest Reg CF rounds in the exemption's history: $27 million raised on SeedInvest at a $275 million valuation. The company had a real product, real customers, and a founder who intentionally excluded traditional VCs in favor of giving retail investors early access.

In December 2022 — six months after closing — NowRx announced shutdown. Assets were sold piecemeal: California patient files went to Alto Pharmacy, Arizona files to Capsule. Creditors holding $15 million in liabilities came first in the liquidation waterfall. Crowdfunding investors who held preferred shares were behind them. Returns for most investors: likely zero.

The autopsy on NowRx is instructive. The company was burning $1.5 million per month. The CEO had expected to raise $40 million but closed at $27 million. When the Fed began hiking rates aggressively in mid-2022, the follow-on VC funding the company implicitly depended on evaporated. Reg CF can substitute for seed capital. It cannot substitute for a VC relationship when a company needs a Series B in a rising-rate environment.

NowRx is not the only cautionary data point. Here, an Airbnb-adjacent property platform, raised $1.3 million from 2,576 investors on Wefunder in 2023 using an uncapped SAFE structure, then shut down six months after closing. Destiny Robotics raised $141,455 from 145 investors on Wefunder in March 2023 before the SEC sued the CEO in 2024 for securities fraud — misrepresenting the company's AI product and executive background. The settlement: $12,990 in disgorgement, $50,000 civil penalty. The 145 investors received nothing.

Understanding how to read a Form C filing before you invest is not optional. Neither is understanding SAFE note risks for early-stage investors.

The Data Gap Nobody Wants to Talk About

Here is the honest finding that should be in every Reg CF marketing piece but isn't: nobody publicly tracks what happened to the 2021-2022 cohort of funded companies.

The SEC DERA white paper documents offering data through December 2024. It does not track post-offering outcomes — whether those 3,869 funded companies are still operating, have been acquired, have gone bankrupt, or stopped filing annual C-AR reports (which in itself is a red flag, since companies that cease operations typically stop filing). KingsCrowd may have proprietary data on this. If they do, it is not publicly available as of this writing.

This is not a minor gap. If you want to evaluate Reg CF as an asset class — the way you would evaluate VC as an asset class — you need 5-year survival rates, exit rates, and investor IRRs across a cohort. None of that data exists publicly for Reg CF. The standard VC benchmark for a 10-year fund is roughly a 2.5x MOIC with a 7-8% annual loss rate at portfolio level. A comparable Reg CF benchmark does not exist. You are investing without a benchmark.

The SEC's own white paper notes that Form C-U (proceeds reporting) filing practices are inconsistent — the $1.546 billion cumulative figure is explicitly described as a lower-bound estimate. If proceeds reporting is incomplete, the outcome data downstream is even less reliable.

The Exceptions That Prove the Rule

The bear case above would be incomplete without the documented wins. They are real. They are rare.

Atlis Motor Vehicles raised multiple rounds via Reg CF and Reg A+ between 2018 and 2021 — the earliest at $0.29 per share on StartEngine. The company listed on NASDAQ in September 2022. IPO opened at $39. Early investors who bought at $0.29 were sitting on 13,000%+ gains on listing day. Trusst, a mental health platform, raised $105,839 on Republic in April 2021 and was acquired by K Health two months later, returning 1.17x to investors.

These deals happen. The question is how often, and whether a $1,500 average check size — the 2024 median investor commitment — gives you enough diversification to find them in a portfolio. At $1,500 per deal, building a 30-company portfolio requires $45,000 committed to early-stage startups with no liquidity, no secondary market of meaningful depth, and no publicly available survival data on the cohort ahead of you.

Secondary market liquidity through StartEngine Secondary and similar ATS (Alternative Trading System) platforms exists in theory. Trading volume data is not publicly disclosed. In practice, illiquidity is the default condition for Reg CF holdings.

What the Risk Actually Looks Like

Here is the honest caveat section that belongs in every piece about Reg CF.

First: the adverse selection problem is structural, not correctable by better due diligence alone. Companies that could raise from institutional angels or seed VCs at comparable valuations generally do. Reg CF systematically attracts companies that professional investors passed on. That doesn't mean they're all bad — plenty of VC-backed companies also fail — but it does mean the base rate for quality is lower than the alternatives.

Second: platform fees consume a real percentage of the capital raised. Typical Reg CF platform fees run 5-7% of the raise plus an equity kicker. For a company raising $114,000 (the 2024 median), that's $5,700-$7,980 in platform fees before accounting for required financial review costs and SEC filing expenses. Small rounds are expensive to run. The money companies raise is not the money they deploy.

Third: the 2025 recovery to $378.3 million is happening on fewer deals, at higher average raise sizes. The market is rewarding companies with demonstrated traction and real investor bases. That is a positive signal for quality. It also means the long tail of undercapitalized companies that ran $50K-$150K Reg CF rounds to stay alive is being winnowed out. If you invested in that cohort between 2021 and 2023, the current market conditions are not your friend.

Fourth: tax treatment matters and is under-discussed. QSBS (Qualified Small Business Stock) exclusions can apply to some Reg CF investments, potentially exempting gains from federal capital gains tax. But QSBS has eligibility requirements — C-corp structure, active business, gross asset limits — that many Reg CF issuers don't meet, particularly those using SAFEs or revenue-share structures. Know your structure before you invest.

What You Should Do With This

If you're an accredited investor evaluating Reg CF as a part of your early-stage portfolio strategy, the EDGAR data points to a few specific actions:

• Demand the Form C. Every Reg CF company must file one. The financial statements are in there. Pull the revenue, the cash burn, the debt load. Compare them to the valuation. A company with $10,000 in revenue and a $15M cap table entry is priced for perfection it hasn't demonstrated.
• Check C-AR filing history. Companies that have raised before and are on their second or third Reg CF round (13.2% of all issuers through 2024, per SEC DERA) have a track record you can actually read. Annual report filings tell you whether the business is growing or not.
• Understand your security structure. Uncapped SAFEs give you downside and capped upside. Preferred equity gives you liquidation preferences that may still leave you behind creditors, as NowRx demonstrated. Know what you own before the round closes.
• Size for total loss. No position in a Reg CF deal should be money you can't afford to lose entirely. The 45% funding rate, the absent survival data, and the liquidity constraints together mean your base case should be illiquidity for 5-10 years or zero return, with upside as the exception rather than the expectation.

None of this means Reg CF is broken. The exemption has genuinely expanded who gets to participate in early-stage investing, and the SEC's own data shows it has channeled meaningful capital to companies — many of them women-led, minority-founded, geographically distributed — that traditional angel networks historically ignored. 34% of 2024 Reg CF issuers had at least one woman founder; the equivalent figure for VC-backed companies is in the low single digits.

But "accessible" and "profitable for investors" are not the same claim. The EDGAR data, read straight, does not yet support the latter at a systemic level. Five years in, the honest answer is: we don't know what the returns are because nobody has published survival-rate data for the full cohort. That gap itself is a finding worth keeping in mind every time you see a platform advertise democratized access to startup investing.

When that cohort data becomes available — and it should, because the SEC raw Form C-AR data is publicly downloadable — it will be the most important story in alternative investing. Until then, the 45% reporting rate is the number you carry with you.

Author Disclosure: The author has no personal LP or shareholder position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.